TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04992741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education and motivational interview
Description: The control group will remain subject to the routine process without any intervention.
Study: NCT04309448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training with functional electrical stimulation
Description: The PBT program will consist of repetitive practice of reactive stepping for one hour. The participants will be equipped with the Odstock 2-Channel stimulator on one or both sides depending on their deficits. One channel of stimulation may be applied to the common fibular nerve to elicit a flexor withdraw reflex and elicit a step. The second channel of stimulation may be applied to the quadriceps muscles to assist with the supporting phase of the reactive step, as required. Participants will experience about 60 perturbations per session during balance exercises. To create a perturbation, the researcher will apply unexpected pushes or pulls to a safety harness around the participant's trunk. Throughout the hour-long session, participants will complete challenging balance tasks, customized to their ability level, during standing and walking. The training will be supervised by a licensed physiotherapist and administered by a licensed physiotherapist or registered kinesiologist.
Study: NCT03600753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: culturomic
Description: Culturomic is a high-throughput culture strategy based on the multiplication of culture conditions coupled with the rapid identification of bacteria by MALDI-TOF (Matrix-Assisted Laser Desorption / Ionization-Time-Of-Flight) mass spectrometry

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metagenomic
Description: Metagenomics is an high throughput sequencing and will be performed using Miseq ( Illumina technology) targeting the V3-V4 hypervariable regions of the 16S RNA gene.

Intervention type: OTHER
Group type: OTHER
Intervention: Metagenomic
Description: Metagenomics is an high throughput sequencing and will be performed using Miseq ( Illumina technology) targeting the V3-V4 hypervariable regions of the 16S RNA gene.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metagenomic
Description: Metagenomics is an high throughput sequencing and will be performed using Miseq ( Illumina technology) targeting the V3-V4 hypervariable regions of the 16S RNA gene.
Study: NCT03092037

Intervention type: PROCEDURE
Intervention: Blood draw
Description: The Investigators will collect serum and whole blood from participants.
Study: NCT03873363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS TKA
Description: Implantation of a posterior stabilized (cruciate substituting) Total Knee Arthroplasty.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CR TKA
Description: Implantation of a cruciate retaining Total Knee Arthroplasty.
Study: NCT02448862

Intervention type: DEVICE
Intervention: Fentanyl based IV-PCA
Description: We have used a disposable PCA pump (Ambix Anaplus®; E-Wha Fresenius Kabi, Korea or accufuser plus®; Woo Young Medical, Korea) and fentanyl was diluted in 100 mL with saline for 48 hrs PCA infusion. The pump was set as follows: infusion rate as 2 ml/hr, bolus dose as 0.5 ml or 1 ml, lockout time as 15 min. It was decided at the anesthesiologist's option whether the additional analgesic drug (ketorolac or nefopam) and the antiemetic drug (ondansetron, ramosetron or palonosetron) would be added in PCA or not. The anesthesiologist who performed the anesthesia decided the amount of chosen drugs.

Intervention type: DEVICE
Intervention: Fentanyl based IV-PCA
Description: We have used a disposable PCA pump (Ambix Anaplus®; E-Wha Fresenius Kabi, Korea or accufuser plus®; Woo Young Medical, Korea) and fentanyl was diluted in 100 mL with saline for 48 hrs PCA infusion. The pump was set as follows: infusion rate as 2 ml/hr, bolus dose as 0.5 ml or 1 ml, lockout time as 15 min. It was decided at the anesthesiologist's option whether the additional analgesic drug (ketorolac or nefopam) and the antiemetic drug (ondansetron, ramosetron or palonosetron) would be added in PCA or not. The anesthesiologist who performed the anesthesia decided the amount of chosen drugs.
Study: NCT00960414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHINE
Description: Both groups will receive a diet and exercise based intervention aimed at eating a caloric intake that will maintain ideal body weight and increasing exercise. SHINE A will emphasize awareness of hunger and satiety cues, while SHINE B will receive more detailed nutritional education.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SHINE
Description: Both groups will receive a diet and exercise based intervention aimed at eating a caloric intake that will maintain ideal body weight and increasing exercise. SHINE A will emphasize awareness of hunger and satiety cues, while SHINE B will receive more detailed nutritional education.
Study: NCT00537095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: 300 mg oral once daily oral dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01444053

Intervention type: DEVICE
Intervention: No Intervention
Description: No Intervention

Intervention type: DEVICE
Intervention: No Intervention
Description: No Intervention
Study: NCT03684330

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: a dose once a week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: whole body vibration (WBV)
Description: 03 months of WBV training three times per week
Study: NCT04008381

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex-vivo Expanded γδ T Lymphocytes
Description: Patients receive ex-vivo expanded γδ T Lymphocytes (Dose escalation, 2\*10\^6, 4\*10\^6, 8\*10\^6 of cells per kg of body weight).
Study: NCT01676363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diflunisal
Description: Open-label diflunisal 500 mg twice daily for 4 weeks
Study: NCT00305825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Study: NCT04279600

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taurine
Description: Taurine supplementation in capsules of 1 gram of taurine powder, total dosage: 3 grams/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Taurine
Description: Taurine supplementation in capsules of 1 gram of taurine powder, total dosage: 3 grams/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplementation in capsules of 1 gram of starch powder, total dosage: 3 grams/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise training
Description: 4 weeks of combined exercise training (alternating strength and aerobic exercise), with a frequency of 3 times/week with 55 min/day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: 4 weeks of combined exercise training (alternating strength and aerobic exercise), with a frequency of 3 times/week with 55 min/day.
Study: NCT01738178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01765998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Clinical evaluation according to the Crohn's activity scale

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01540539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1154 or placebo
Description: Participants will receive active drug or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1154 or placebo
Description: Participants will receive active drug or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1154 or placebo
Description: Participants will receive active drug or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1154 or placebo
Description: Participants will receive active drug or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1154 or placebo
Description: Participants will receive active drug or placebo
Study: NCT03684330

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whole body vibration (WBV)
Description: 03 months of WBV training three times per week
Study: NCT02197741

Intervention type: DRUG
Intervention: opiate with bolus

Intervention type: DRUG
Intervention: opiate with bolus
Study: NCT01960296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Continue home dose of clopidogrel into surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Discontinue Clopidogrel
Description: Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
Study: NCT03653299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo or Active Phototherapy (MR4)
Description: Phototherapy, placebo or active, will applied in 9 different points of anterior muscle of the thigh, 6 different points of posterior muscle of the thigh and 2 different points of the gastrocnemius muscle, bilaterally. Once a week during for 4 weeks, before the tests, the phototherapy programs (1, 2, 3 and 4) order will depend of the group randomized. The 10 subjects will do the three-dimensional gait analysis, muscle activity during gait, evaluation of mobility, static and functional balance, and mobility tests.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo or Active Phototherapy (MR4)
Description: Phototherapy, placebo or active, will applied in 9 different points of anterior muscle of the thigh, 6 different points of posterior muscle of the thigh and 2 different points of the gastrocnemius muscle, bilaterally. Once a week during for 4 weeks, before the tests, the phototherapy programs (1, 2, 3 and 4) order will depend of the group randomized. The 10 subjects will do the three-dimensional gait analysis, muscle activity during gait, evaluation of mobility, static and functional balance, and mobility tests.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo or Active Phototherapy (MR4)
Description: Phototherapy, placebo or active, will applied in 9 different points of anterior muscle of the thigh, 6 different points of posterior muscle of the thigh and 2 different points of the gastrocnemius muscle, bilaterally. Once a week during for 4 weeks, before the tests, the phototherapy programs (1, 2, 3 and 4) order will depend of the group randomized. The 10 subjects will do the three-dimensional gait analysis, muscle activity during gait, evaluation of mobility, static and functional balance, and mobility tests.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo or Active Phototherapy (MR4)
Description: Phototherapy, placebo or active, will applied in 9 different points of anterior muscle of the thigh, 6 different points of posterior muscle of the thigh and 2 different points of the gastrocnemius muscle, bilaterally. Once a week during for 4 weeks, before the tests, the phototherapy programs (1, 2, 3 and 4) order will depend of the group randomized. The 10 subjects will do the three-dimensional gait analysis, muscle activity during gait, evaluation of mobility, static and functional balance, and mobility tests.
Study: NCT00838188

Intervention type: OTHER
Intervention: Way of Feeding - Breast feeding vs. Bottle feeding
Description: Each infant was evaluated twice, once after breastfeeding and once after bottle feeding of breast. Computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence

Intervention type: OTHER
Intervention: Way of Feeding - Breast feeding vs. Bottle feeding
Description: Each infant was evaluated twice, once after breastfeeding and once after bottle feeding of breast. Computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence

Intervention type: OTHER
Intervention: Way of Feeding - Breast feeding vs. Bottle feeding
Description: Each infant was evaluated twice, once after breastfeeding and once after bottle feeding of breast. Computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence

Intervention type: OTHER
Intervention: Way of Feeding - Breast feeding vs. Bottle feeding
Description: Each infant was evaluated twice, once after breastfeeding and once after bottle feeding of breast. Computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
Study: NCT01540539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1154 or placebo
Description: Participants will receive active drug or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1154 or placebo
Description: Participants will receive active drug or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1154 or placebo
Description: Participants will receive active drug or placebo
Study: NCT03100292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy or Roux-en-Y gastric bypass
Study: NCT01652833

Intervention type: OTHER
Intervention: Physician Survey
Description: Eligible physicians will be contacted via telephone to perform the physician survey. A standardised questionnaire will be used to collect information about the physician's awareness of the correct indication and appropriate administration of Vectibix and the physician's experience in the administration of Vectibix treatment in the previous 6 months

Intervention type: OTHER
Intervention: Physician Survey
Description: Eligible physicians will be contacted via telephone to perform the physician survey. A standardised questionnaire will be used to collect information about the physician's awareness of the correct indication and appropriate administration of Vectibix and the physician's experience in the administration of Vectibix treatment in the previous 6 months
Study: NCT01152138

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open cells stent
Description: Cobalt Chromium Stent with open cell design

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Cells Stent
Description: Cobalt Chromium stent with closed cell design
Study: NCT00950027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: povidone iodine
Description: oropharyngeal decontamination every 4 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oropharyngeal decontamination every 4 hours
Study: NCT02328716

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cytoreduction
Description: Cytoreduction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreduction
Description: Cytoreduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hipec with Cisplatin
Description: Intraoperative Intraperitoneal Hyperthermic Chemotherapy (Hipec)+Cisplatin
Study: NCT00575796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulphate
Description: Vinblastine dose: 6 mg/m2 (10 mg maximum dose) route intravenous administration once a week.
Study: NCT00058799

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 1
Description: Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 2 x 10\^5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 2
Description: Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 2 x 10\^5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 3
Description: Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 4.2 x 10\^7
Study: NCT00947154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
Study: NCT05306678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting
Description: After consuming breakfast, participants sat on a chair for 180 min. After 180 min, lunch was provided. After finishing lunch, participants sat on a chair for another 120 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breaking sitting
Description: After consuming breakfast, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, lunch was provided. After finishing lunch, participants continued 2 min of walking every 20 min for the following 120 min.
Study: NCT02171715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 MA2
Description: film-coated immediate release tablet - final formulation
Study: NCT00838188

Intervention type: OTHER
Intervention: Way of Feeding - Breast feeding vs. Bottle feeding
Description: Each infant was evaluated twice, once after breastfeeding and once after bottle feeding of breast. Computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
Study: NCT03432663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone(1)
Description: Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 h was reached

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone(2)
Description: Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 h for up to 72 h or until sinus rhythm was reached
Study: NCT01468623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic 5-FU dose adjustment using OnDose® assay
Description: OnDose is a commercially available assay to measure concentration of 5-FU exposure.
Study: NCT00161421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Testosterone
Description: 200 mg (Formulation A) Day 1 400 mg (Formulation A) Day 2, fasting; Day 3, with food 200 mg (Formulation B) Day 8, fasting 400 mg (Formulation B) Day 9, fasting; Day 10, with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide (Lupron)
Description: 7.5 mg injection into muscle (once) (Day -14)
Study: NCT01468623

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients' dose of 5-FU will be based on Body Surface Area (BSA).
Study: NCT02873832

Intervention type: BIOLOGICAL
Intervention: Blood sample

Intervention type: BIOLOGICAL
Intervention: Blood sample

Intervention type: OTHER
Intervention: Flow cytometry

Intervention type: OTHER
Intervention: Flow cytometry

Intervention type: OTHER
Intervention: western blot

Intervention type: OTHER
Intervention: western blot
Study: NCT02189811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: IPV at birth, 6, 10, 14 weeks of age and tOPV at 18 and 22 weeks of age
Study: NCT02744547

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina
Description: Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
Study: NCT02189811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bOPV
Description: bOPV at birth, 6, 10, 14 weeks and tOPV at 18 and 22 weeks of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bOPV and IPV
Description: bOPV till week 10, bOPV+IPV at 14 and tOPV at 18 and 22 weeks of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bOPV and IPV and IPV2
Description: bOPV till week 10, bOPV+IPV at 14, tOPV+IPV2 at 18 and tOPV at 22 weeks of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tOPV
Description: tOPV till 22 weeks of age
Study: NCT01951027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-G3 12.5 μg/kg or Placebo
Description: Single SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-G3 25 μg/kg or Placebo
Description: Single SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-G3 50 μg/kg or Placebo
Description: Single SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-G3 100 μg/kg or Placebo
Description: Single SC injection
Study: NCT00968968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Oral Lapatinib 1000 mg once daily. Lapatinib was a small molecule, reversible inhibitor targeting HER2 tyrosine kinase receptor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: IV Trastuzumab 6 mg/kg every three weeks. Trastuzumab was a humanized, monoclonal antibody directed against the extracellular domain of the HER2 tyrosine kinase receptor.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: IV Trastuzumab 6 mg/kg every three weeks. Trastuzumab was a humanized, monoclonal antibody directed against the extracellular domain of the HER2 tyrosine kinase receptor.
Study: NCT03116269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study: NCT03446768

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peer support
Description: Access to educational and informational support by a trained peer coach
Study: NCT00870155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dirucotide
Description: 500mg, intravenous, every 6mos until regulatory approval, denial or sponsor termination
Study: NCT01691313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanoxerine
Description: single oral dose
Study: NCT02171715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 MA2
Description: film-coated immediate release tablet - trial formulation II
Study: NCT03446768

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peer support
Description: Access to educational and informational support by a trained peer coach

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online platform
Description: An online platform that provides educational, informational and access to several therapeutic device metrics

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Therapist support
Description: Limited medical support provided by trained Respiratory Therapists.
Study: NCT02171715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBW 2992 MA2
Description: powder for oral solution